A novel gradient reversed-phase ultra performance liquid chromatographic method has been developed for quantitative determination of Esomeprazole magnesium and its seven impurities in pharmaceutical dosage forms. Chromatographic separation has been achieved on an Acquity BEH C18, 50mm×2.1mm, 1.7μm with buffered mobile phase consisting solvent A (0.04molar (M) glycine (pH 9.0) buffer) and solvent B (mixture of acetonitrile and Milli-Q water in the ratio 90: 10 (v/v); respectively) delivered at flow rate of 0.21mL min(-1) and the detection wavelength 305nm. Resolution of Esomeprazole magnesium and all the seven potential impurities has been achieved greater than 2.0 for all pairs of compounds. The drug was subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal and photolytic degradation. Esomeprazole magnesium was found to degrade significantly in oxidative and acid hydrolysis stress conditions and stable in base, hydrolytic and photolytic degradation conditions. The degradation products were well resolved from main peak and its impurities, thus proved the stability indicating power of the method. The stress samples were assayed against a reference standard and the mass balance was found to be close to 99.1%. So this method was also suitable for Assay determination of Esomeprazole magnesium in pharmaceutical dosage forms. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection, limit of quantification, accuracy, precision and robustness.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpba.2011.08.025 | DOI Listing |
J Prev Med Public Health
December 2024
Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
Objectives: This study was performed to evaluate the utilization patterns of acid suppressants following the withdrawal of ranitidine in Korea.
Methods: Health Insurance Review & Assessment Service (HIRA) data from January 2016 to May 2023 were utilized to assess the usage of histamine H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) for acid-related diseases. Drug utilization was calculated for each agent based on the defined daily dose (DDD).
BMC Health Serv Res
January 2025
NOVA National School of Public Health, NOVA University Lisbon, Lisbon, Portugal.
Background: Proton-pump-inhibitors (PPIs) are overprescribed, posing challenges to patients and healthcare systems. In Portugal, the public National Health Service (NHS) provides universal coverage and reimburses medication regardless of prescription origin, i.e.
View Article and Find Full Text PDFClin Exp Dermatol
January 2025
Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Créteil, France.
Background: Epidermal necrolysis (EN) is a rare and severe condition, characterized by a diffuse skin and mucosal detachment and mainly induced by drugs. Literature is scarce regarding the rate of recurrences and culprit drug re-exposure.
Objectives: To assess the rate of EN recurrences as well as high notoriety drugs re-exposures in patients with EN.
Am J Case Rep
January 2025
Medical School, University of Western Australia, Fremantle, Western Australia, Australia.
BACKGROUND Although hypomagnesemia is common in type 2 diabetes, clinical presentations with severe hypomagnesemia are rare. A number of oral blood glucose-lowering medications can reduce serum magnesium concentrations, and several severe cases have been reported in the presence of marked glucagon-like peptide-1 receptor agonist (GLP-1RA)-associated gastrointestinal adverse effects. In the present case, an acute presentation with severe hypomagnesemia was likely due to polypharmacy including semaglutide, albeit with a delayed relationship to discontinuation of this GLP-1RA, due to nausea and vomiting.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of Vascular Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University/Second Military Medical University, Shanghai, China.
Background: Proton pump inhibitors (PPIs) are effective treatments for acid-related disorders but may pose tumor risks with long-term use. Current research on PPI-associated tumor adverse events (TAEs) is limited and inconclusive. This study aims to comprehensively analyze the relationship between PPIs and TAEs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!